Bioprocessing - Upstream & Downstream

A video interview discussing the challenges of viral vectors

Download our eBook to find out how the industry is trying to be more sustainable.

Why 2023 is the year that antibody manufacturers should embrace CRISPR gene editing.

Great successes are being seen in gene therapy, but there are still gaps in our scientific knowledge – and our manufacturing prowess.

Demand for cell and gene therapies is increasing, but are current manufacturing approaches up to the task?

Voting is now open for the 2023 Company of the Year Awards – make sure you have your say!

Our free eBook showcases content on bioprocess scale up, biosimilars, primary packaging considerations, and more.

Sartorius shares its vision for better, faster, and cheaper bioprocessing.

Exploring the potential of self-amplifying RNA and circular RNA in the future of drug development.

Determining full versus empty capsids remains a key challenge with adeno-associated viral vectors.